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Abstract
Background: Depression is a commonly occurring disorder linked to diminished role functioning and quality of life.
The development of treatments that overcome barriers to accessing treatment remains an important area of clinical
research as most people delay or do not receive treatment at an appropriate time. The workplace is an ideal setting
to roll-out an intervention, particularly given the substantial psychological benefits associated with remaining in the
workforce. Mobile health (mhealth) interventions utilising smartphone applications (apps) offer novel solutions to
disseminating evidence based programs, however few apps have undergone rigorous testing. The present study
aims to evaluate the effectiveness of a smartphone app designed to treat depressive symptoms in workers.
Methods: The present study is a multicentre randomised controlled trial (RCT), comparing the effectiveness of the
intervention to that of an attention control. The primary outcome measured will be reduced depressive symptoms
at 3 months. Secondary outcomes such as wellbeing and work performance will also be measured. Employees from
a range of industries will be recruited via a mixture of targeted social media advertising and Industry partners.
Participants will be included if they present with likely current depression at baseline. Following baseline assessment
(administered within the app), participants will be randomised to receive one of two versions of the Headgear
application: 1) Intervention (a 30-day mental health intervention focusing on behavioural activation and
mindfulness), or 2) attention control app (mood monitoring for 30 days). Participants will be blinded to their
allocation. Analyses will be conducted within an intention to treat framework using mixed modelling.
Discussion: The results of this trial will provide valuable information about the effectiveness of mhealth
interventions in the treatment of depressive symptoms in a workplace context.
Trial registration: The current trial is registered with the Australian and New Zealand Clinical Trials Registry
(ACTRN12617000547347, Registration date: 19/04/2017).
Keywords: Depression, Workplace, Mhealth, Treatment
Background
Depression is now recognised as one of the leading
causes of disability worldwide [1]. As well as being rela-
tively common [2], depression can also be very debilitat-
ing [3], with core symptoms inclusive of; an absence of
positive affect, persistent low mood, and low activity [4].
Persons with severe depressive symptoms report serious
difficulties in all aspects of their life, including work,
home, and social activities [5]. In response to the
increased identification and recognition of depression
[6], there has been greater emphasis on the development
of innovative and effective psychological treatments.
The treatment of depression, both pharmacologically
and with non-pharmacological interventions, remains a
critical area of ongoing clinical research. There is substan-
tial evidence supporting the efficacy of psychotherapy in
the treatment of both sub-clinical [7] and clinical levels of
depression [8]. Whilst cognitive behaviour therapy (CBT)
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remains the most empirically supported treatment [9],
other therapies such as behavioural activation therapy
(BAT) has been shown to be equally effective and also less
complex to administer [10]. Service use statistics indicate
that despite the effectiveness of such treatments, few
people readily access these services [11]. Overcoming
identified barriers to accessing psychotherapy such as cost,
convenience and accessibility [12] may enhance people’s
ability to access evidence based treatments.
Despite experiencing depression many people still re-
main as active participants in the workforce [13]. Ongoing
employment is associated with numerous individual bene-
fits such as economic, psychosocial, and emotional well-
being [14]. Given its immediacy and core role in the lives
of individuals, the workplace may be an avenue for provid-
ing psychological interventions to those who might not
otherwise access mental health services in a conventional
manner [15]. Interventions implemented in the workplace
have been found to be effective in improving both mental
health and occupational outcomes [16]. This highlights an
added benefit of workplace interventions as medical inter-
ventions in isolation have not shown as positive an effect
on work-related outcomes when compared to workplace
interventions [17]. To date, most workplace interventions
face accessibility and scalability issues, thus limiting the
opportunity for employees to access these services. This
issue appears to be particularly prevalent in workers
employed in industries where roles are mobile and/or iso-
lated; work hours are often intermittent or excessive; and
tasks may be repetitive and high-risk (e.g. such as con-
struction, transport and mining). These industries tend to
be male-dominated (males > 70% of workforce) [18] and
are associated with higher rates of mental health concerns
[18]. Technological innovations, namely smartphones,
provide an opportunity for individuals in such roles to
learn how to manage their wellbeing and seek further sup-
port if required [19].
Mobile health (mhealth) technologies are increasingly
being recognised as an effective means through which
mental health interventions can be disseminated in the
population [20, 21]. Such interventions overcome numer-
ous barriers associated with treatment seeking, including
stigma, cost, and accessibility [20]. Encouragingly, there is
preliminary support that mhealth interventions can effect-
ively treat symptoms in adults with depression [22]. More-
over, mhealth interventions offer the opportunity for an
autonomous, user-directed approach that motivates and
offers personalised support by allowing the delivery of
content to be tailored to an individual’s interests and
needs [23]. This may be particularly advantageous to
workplace contexts where, individualised interventions
are associated with more consistent outcomes than organ-
isational wide interventions [24]. However, of the many
mhealth interventions available on the market, few have
been trialled [20] and even fewer have been specifically
tailored to a workplace setting.
The proposed HeadGear trial aims to evaluate the
effectiveness of a new smartphone app in treating
depressive symptoms in a workplace context.
Methods
Design
The aim of the current study will be achieved through a
multicentre randomized controlled trial, with two parallel
arms. The trial will compare two smartphone app-based in-
terventions: a novel intervention app designed for the treat-
ment of depression (Headgear) and an attention control
app (mood monitoring). Assessments will occur at baseline,
post-intervention (5-weeks), and at 3-month follow-up.
The study is registered with the Australian New Zealand
Clinical Trials Registry (ACTRN12617000547347) and has
ethical approval from the University of New South Wales
(UNSW) Human Research Ethics Committee (HC17021).
Consent to participate in the trial will be obtained electron-
ically from all participants. The study will be conducted in
accordance with the Helsinki Declaration [25] and is com-
pliant with the CONSORTguidelines [26].
Setting and participants
The study will recruit Australians who are currently
employed, and will sample more selectively from a range
of male-dominated industries [27]. In Australia, these
industries include agriculture/forestry/fishing, utility ser-
vices (electricity, gas, water and waste), wholesale trade,
manufacturing, transport/postal/warehousing, mining,
and construction [28]. Emergency services and defence
also fit this definition, but were not considered unique
industries by the ABS, though for this study they will
also be considered as male-dominated.
Industry partner organisations will assist with recruit-
ment by promoting the study among specific groups or
their entire workforce. We will aim to recruit at least
850 employed adults across Australia. Organisations that
elected to participate will promote the study via their
respective health and wellbeing officers, along with email
and newsletter advertisements. The study will also be
promoted via members of the research team presenting
at partner worksites. Social media advertising targeted at
employed people will also be utilised to recruit individ-
uals employed externally of partner organisations using
an evidence-informed advertising approach [29]. Both
males and females will be recruited.
Eligibility criteria
Initial eligibility criteria are: having a valid telephone num-
ber, ownership of an Apple/Android-operating smartphone,
fluent in English and living in Australia. As this trial is
focused on the treatment of depression, participants will
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also be excluded from this trial (although still permitted to
use the app) if they do not have substantial levels of depres-
sive symptoms at baseline, as indicated by either a PHQ-9
score below 15, or the PHQ-9’s algorithm for a diagnosis
for Major Depressive Disorder (MDD) not being met [30].
Participants were excluded if they were under 18 or not
currently employed. No exclusion criteria were in place
regarding comorbidities or medication use.
Interventions
Active intervention: HeadGear
The intervention condition, HeadGear, is a smartphone
application-based intervention utilising Behavioural Acti-
vation Therapy (BAT) and mindfulness-based therapies.
Behavioural Action is a therapy based on learning theory
that reconnects people to an environment of positive
reinforcement, incorporating elements of value driven ac-
tion and goal setting [31, 32]. When delivered face-to-face,
BAT has been shown to perform as well as CBT for the
treatment of depression [33] and preliminary evidence
that this translates in mhealth form [34]. The other com-
ponent utilised in Headgear, Mindfulness, draws on medi-
tation practices to allow individuals to gain further insight
into their emotional, physical, and/or cognitive experience
to ultimately shape it [35]. Mindfulness has been identified
as a transtherapeutic process that targets transdiagnostic
mental processes [36], as evidenced by its effect in treating
a range of psychopathologies including but not limited to
mood, anxiety and substance use disorders [37, 38].
The therapeutic component of HeadGear encourages
the user to complete one ‘challenge’ each day (5–10 min
per day), over 30 days. These ‘challenges’ incorporate a
variety of evidence-based BAT and mindfulness tech-
niques and skills, including psychoeducational videos,
value-driven activity planning and goal-setting, practice
exercises, and techniques for developing coping and
resilience (e.g., problem solving, improving sleep, mini-
mising alcohol use, and/or assertiveness training). Other
components of the Headgear intervention app include
mood monitoring, a skill ‘toolbox’ (progressively built as
the skills are completed), and a technical service help-
line. Steps have been taken to promote user motivation
and engagement by incorporating a ‘daily challenge’
framework where the user is ‘rewarded’ (through skill
tokens) upon completing each daily challenge. A chal-
lenge framework has been shown to increase the general
appeal of an app [39–41]. In addition to these elements,
the Headgear application has been designed using par-
ticipatory approaches and iterative human-computer
interaction design strategies [42, 43].
Attention-matched control
The attention-matched control condition is a smart-
phone application that will have the same name and a
virtually identical look and ‘feel’ as the intervention
version of Headgear and is accessed in the same man-
ner. However, there is no skill development and no
component of behavioural activation or mindfulness
therapy. To control for the attentional component of the
HeadGear application, the control condition will en-
courage users to use the inbuilt mood monitor daily over
a 30-day period and users will also have access to the
‘risk calculator.’
Procedure
All interested users will be directed to their respective
app store (iTunes or Google Play) directly via a dedi-
cated website (headgear.org.au) where participants regis-
ter and provide their phone number. Informed consent
will be sought digitally via both the website and the app
itself. This provides information around the study aims,
risks and benefits, confidentiality and dissemination of
results. After consent and app download participants
will undergo initial screening. Participants who meet the
inclusion criteria will then be randomised to receive ei-
ther the full HeadGear app or the attention-matched
control version of the app. Participants will be blinded
to their allocation. All participants will be provided with
appropriate referral information to health services and
crisis lines and will be encouraged to seek help from
their GP (if this has not already occurred) while com-
pleting the trial. The flow of participants through the
study phases is shown in Fig.1.
Random allocation
Randomisation will occur immediately following comple-
tion of the baseline assessment using automated proce-
dures integrated into the trial management software. The
algorithm for randomisation will consist of a block design,
stratified by industry type, with a block size of 10.
Assessment
Administration of assessments
Assessments will be completed at baseline, post-intervention
(5-weeks), and 3-month follow-up. Baseline assessment
includes outcome measures pertaining to depression symp-
tomatology (Patient Health Questionnaire (PHQ-9) [44]),
wellbeing (World Health Organisation-5 (WHO-5)
Well-Being Index [45, 46]), anxiety symptomatology (Gen-
eral Anxiety Disorder-2 item (GAD-2) [47], resilience (Con-
nor-Davidson Resilience Scale 10-item (CD-RISC10) [48]),
work performance and absenteeism (Health and Work
Performance Questionnaire (HPQ) [49]). In addition to
these measures, demographic and service use information
will be collected. The application monitors usage data in-
cluding number of log-ins, frequency of use, time spent
in-app, and activity completion rates. This data will be used
to examine program engagement.
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Post-intervention assessment will occur at 5 weeks’
post-baseline, to allow users extra time to complete the
30-day program. Participants will be reminded to complete
the post-intervention assessment via text messages to
phone numbers provided in order to address for the possi-
bility that users may delete the app during the trial. Partici-
pants will complete an online questionnaire similar to the
baseline measure (see Table 1), and again at 3 months
post-baseline (“3-month follow-up”). Participants will
receive up to three text messages and a call at each
follow-up assessment time point, linking them to an online
platform through which they can complete the assessment.
On completion of each assessment, participants will be
entered into a draw to win one of four $200 Visa gift cards.
Specific measures used in online assessments
The PHQ-9 will be used to measure depression symptom-
atology [50]. The PHQ-9 is a reliable and valid nine-item
Fig. 1 Flow of participants through the trial
Table 1 Assessment measures
Baseline Post-intervention 3-month follow-up
Demographics ×
Patient Health Questionnaire-9 item (PHQ-9) [44] × × ×
General Anxiety Disorder-2 item (GAD-2) [47] × × ×
World Health Organisation-5 (WHO-5) Well-Being Index [45, 46] × × ×
Connor-Davidson Resilience Scale 10-item (CD-RISC10) [48] × × ×
Health and Work Performance Questionnaire (HPQ) [49] × × ×
Service utilisation and management items × × ×
Program feedback ×
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measure of depression severity over the past 2 weeks [44,
51]. Each of the nine items of the PHQ-9 is scored as 0
(not at all), 1 (several days), 2 (more than half the days), or
3 (nearly every day). Scores are summed to provide a total
score (score range 0–27 with 0 indicating no depressive
symptoms and 27 indicating all symptoms occurring
nearly daily). The criterion and construct validity of the
PHQ-9 has previously been demonstrated, with 73% sensi-
tivity and 98% specificity in detecting major depression
compared to clinician-based assessment [28, 50] and,
regardless of diagnostic status, typically represents clinic-
ally significant depression [50]. The measure has excellent
internal consistency (Cronbach α > 0.85 in multiple sam-
ples) and test-retest reliability (α = 0.84) [52].
Anxiety will be measured using the 2-item Generalised
Anxiety Disorder scale (GAD-2) [47]. The GAD-2
consists of the two core criteria for generalized anxiety
disorder, which have been shown to be effective screen-
ing items for panic, social anxiety, and post-traumatic
stress disorders [47]. The GAD-2 begins with the stem
question: “Over the last 2 weeks, how often have you
been bothered by the following problems?” Response
options are “not at all”, “several days”, “more than half
the days”, and “nearly every day”, scored as 0, 1, 2, and
3, respectively (total ranging from 0 to 6). A total scale
score ≥ 3 is suggested as a cut-off point between the nor-
mal range and “probable anxiety” [47].
Resilience will be measured by the 10 item
Connor-Davidson Resilience Scale (CD-RISC-10) [53].
The CD-RISC-10 is a self-rated measure, with each
question rated on a 5-point scale from 0 (‘not true at
all’) to 4 (‘true nearly all the time’). The CD-RISC-10
has been shown to differentiate between individuals
who function well after adversity and those who do not
and measures the core features of resilience and the
ability to tolerate experiences [53]. It is believed that
increased resilience may reduce rates of mental ill
health [54].The scale demonstrates high internal
consistency (Cronbach’s α = 0.89), construct validity,
and test-retest reliability in the general population and
in clinical settings [48]. Total scores range from 0 to 40
with higher scores corresponding to greater resilience.
The scale has been shown to have good concurrent
validity, with higher resilience on the scale associated
with lower levels of perceived stress [48] Validity is high
relative to other measures and reflects differentiation in
resilience among diverse populations, showing that
higher levels of resilience are consistent with lower
levels of perceived stress vulnerability [48].
Wellbeing will be assessed using the 5-item WHO
Wellbeing Index (WHO-5) [45, 46]. Participants are
asked to self-report on the presence or absence of well-
being on a 6-point scale ranging from 5 (‘all of the time’)
to 0 (‘none of the time.’) Raw scores range from 0 to 25
where 0 indicates the worst possible quality of life while
a score of 25 represents the best possible quality of life.
A score ≤ 13 or an answer of 0 or 1 on any of the five
items shows poor wellbeing. WHO-5 is a psychometric-
ally sound measure of well-being with high internal
consistency (Cronbach’s α = 0.84) and convergent associ-
ations with other measures of well-being [55].
Work Performance will be measured using three items
(performance items A10, A11, A12) from the Health and
Work Performance Questionnaire (HPQ) [49]) and two
additional items pertaining to: i) sickness absence over
the past month (days absent more generally, and days
absent specifically for mental health reasons), and ii)
weeklong sickness absence over the past 6-months
(weeks absent more generally, and weeks absent specific-
ally for mental health reasons).
Service use and management items comprised of seven
items assessing lifetime and past month service use,
along with current medication use. Participants were
also asked about their abilities (perceived capability and
effectiveness) to manage their mental fitness, and auton-
omy (choice and freedom) in management. These were
scored on a 7-point Likert scale from strongly disagree
to strongly agree.
Safety protocol
In any trial concerned with mental health, there is the po-
tential for participants to experience psychological dis-
tress. Those who meet criteria for the trial will within the
app trigger the user to be directed to a “get support” page
(at each assessment point) and will suggest the participant
seek further help from these support services or their gen-
eral practitioner (GP). Additionally, an optional call-back
service for individuals requiring further support or direc-
tion is provided. This call-back will be conducted by a
team-member with psychology training, within 4 days,
with the purpose to guide participants into necessary care
arrangements. If the team member still has concerns for
the participant’s safety, an accredited psychiatrist will con-
tact the participants within the next 24 working hours.
Participants will also receive an SMS with a range of sup-
port service contacts, and another reminder to consult
with their GP regarding their mental health.
Study hypotheses and outcomes
We hypothesise that participants receiving the HeadGear
intervention will have reduced levels of depression symp-
tomatology at post-intervention and 3-month follow-up,
compared to participants in the attention-matched control
condition. While the primary analyses will be conducted on
the entire sample (to examine the intervention effect). We
also predict the intervention effect to vary according to the
level of depression symptoms at baseline [56], with a greater
effect amongst those with higher levels of symptomatology.
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Secondly, it is hypothesized that—relative to the control
group—HeadGear Intervention participants will have
lower rates of depressive disorder as detected by the PHQ
algorithm at all follow-up time points. We also hypothe-
sise that the intervention group will have reduced levels of
anxiety symptomatology, and improved wellbeing, resili-
ence, and work performance, at all follow-up time points,
relative to controls.
Primary outcome
The primary outcome measure of the study will be the
level of depressive symptomatology (as measured by the
PHQ-9) at the 3-month follow up period.
Secondary outcomes
A range of secondary outcomes will be considered, includ-
ing change in anxiety symptomatology (as measured by
the PHQ-2) at both 5-week and 3-month follow up. Other
secondary outcomes include incident caseness of depres-
sion at 5-week and 3-month follow-up (as measured by
the PHQ-9 diagnostic algorithm), and the level of depres-
sion symptoms (PHQ-9) at 5-week follow up. Finally,
change in Wellbeing (as measured by the WHO-5) and
change in occupational functioning (as measured by the
HPQ and sickness absence questions) at both 5-week and
3-month follow-ups will be outcomes of interest.
Statistical analysis
Analysis plan
Primary analyses will be undertaken on an intent-to-treat
basis, including all participants as randomised, regardless
of treatment received or withdrawal from the study. Like-
lihood based methods (mixed-model repeated measures
(MMRM)) methods will be favoured to analyse change in
the primary outcome measure (PHQ-9). A priori planned
comparisons of change from baseline across the 3-month
follow up period will be used to test the primary hypoth-
esis. An unstructured variance-covariance matrix will be
used to accommodate relationships between observations
at different occasions. Variables found to be substantially
imbalanced between groups post randomisation will be
tentatively included in these models and retained if
statistically significant and influential on outcomes. Simi-
lar analyses of scaled secondary measures will assess
differential change due to intervention arm. Mathematical
transformation or categorisation of raw scores may be
undertaken to meet distributional assumptions and ad-
dress any violation of assumptions attributable to outliers.
Baseline characteristics will be used to define subgroups
that would be the targeted if the app were offered as treat-
ment. Group membership will be used for models to evalu-
ate moderation of effectiveness by adding appropriate
interaction terms and undertaking planned comparisons.
The effect on outcome of level of baseline depressive
symptom levels, level of functional improvement and re-
cruitment method at baseline will be explored using an
analysis of covariance approach using baseline measures as
a covariate and including a covariate by intervention arm
interaction term in models. The effectiveness of the active
intervention at clinically relevant levels of baseline covari-
ates will be assessed using planned comparisons while the
lowest values of covariates associated with a significant
benefit of the intervention will be established using a
Johnson and Neyman [57] approach.
All tests of treatment effects will be conducted using a
two-sided alpha level of 0.05 and 95% confidence intervals.
Sample size
As a treatment, the size of the effect of the intervention
is anticipated to be moderate. Meta-analysis of previous
trials of internet and mobile based treatment of depres-
sion showed a large effect size of g = − 0.90 [22]; how-
ever unguided interventions typically show smaller effect
sizes. Power calculations were carried out using the R
package simR [58]. Power was set at 80%, alpha at 0.05,
2-tailed tests, and a correlation of .50 between pre- and
post- intervention scores was assumed. Based on these
calculations, a sample size of 266 per group was needed
(total N = 532). A conservative dropout rate of 40% at
follow-up was estimated. An initial sample of 851 will
therefore be recruited for the trial.
Dissemination
Results of this study will be disseminated for publication
in peer-reviewed journals and key findings presented at
national and international conferences.
Discussion
This study is planned to be the largest randomised con-
trolled trial of a smartphone intervention for depression.
By targeting the workers, this trial will provide valuable
evidence regarding the effectiveness of mhealth interven-
tions in treating depressive symptoms in a workplace
context. Given the substantial impact that depression
has on the individual and the employer, if shown to be
effective, this program would allow for a simple and eco-
nomical means by which an organisations or govern-
ments could disseminate a tailored intervention for
workers. Given the proliferation of untested smartphone
applications, the dissemination of evidence based prod-
ucts into the workplace, and indeed the wider commu-
nity, remains a pressing need.
Employees with significant depressive symptoms have
higher rates of absenteeism, presenteeism and job turnover
[59]. Remaining in the workforce is important as it offers
structure, empowerment, financial security and protection
from the psychological impacts of unemployment [14].
Using the workplace as a means to dispense or promote an
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intervention may not only be protective for the individual
concerned, but may also assist in overcoming the issue of
individuals delaying or not receiving treatment [60]. From
an economic standpoint, it is has been established that, for
the workplace, such an approach is more cost-effective for
the organisation [61]: utilising smartphone technologies
would improve upon this cost-effectiveness. It is also hoped
that dissemination via workplaces and social media will
help engage individuals who would not usually access help
via the health care system.
This study will provide valuable evidence regarding the
effectiveness of mhealth tools in the treatment of depres-
sive symptoms. Despite the proliferation of mental health
apps, there is scarce research on the effectiveness of such
apps. Indeed, in a systematic review of the literature on
smartphone interventions, only five mental health apps
were empirically tested and only one of these did not re-
quire the input from a mental health professional [20].
mHealth interventions offer advantages in that they in-
crease user autonomy and anonymity, which may be im-
portant as stigma [62] and lack of knowledge of services
[63] can impact upon help-seeking behaviour in the work-
place. An intervention developed for the workplace also
carries the benefit in that it could ameliorate some of the
financial burden placed solely on the healthcare system.
The proposed trial does carry with it a number of limi-
tations. The use of a smartphone app as a delivery mo-
dality does mean that the intervention is unguided and
that the user is responsible for managing their inter-
action with the program. Thus, trial attrition and disen-
gagement are expected issues [64, 65]. It is worth
noting, however, that this has also been an issue for
face-to-face psychotherapy trials [66]. The reason for
drop out in both mhealth and face-to-face trials is often
multi-faceted, and whilst can be related to engagement
with the program, it is rarely only due to dissatisfaction
[67].To account for potential drop out, two procedures
were put into place. Firstly, all follow-up communication
would occur via phone numbers to ensure that if the
participant uninstalled the app before the follow-up
period, the participant could still be reached. Secondly,
conservative drop-out estimation and the use of statis-
tical methods robust to data missing at random, it is
believed that this limitation will be minimised.
Another limitation of the present trial is related to the reli-
ance on self-reported depressive symptoms, rather than a
diagnosis of depression achieved through a structured diag-
nostic interview. This is a common issue faced by most
similar trials given the constraints around time and re-
sources. To overcome this issue, we will use a well-validated
measure (PHQ-9) that contains two methods for classifying
depression: 1) threshold total score above 14 (sensitivity =
67%; specificity = 95%) [68] or 2) meeting the depression
algorithm’s criteria (sensitivity = 0.53; specificity = 0.94) [69].
By using both methods, we are confident that participants
without significant symptomatology will be excluded and
those with significant symptomatology will be included.
The treatment of depression utilising evidence based
mhealth interventions remains an important area of clinical
research. The Headgear trial will be the largest trial of a
smartphone application that seeks to offer an alternate or
augmentation to traditional face-to-face therapy through
which working adults can manage their mental health and
wellbeing. This trial will be unique in that it is advertising a
treatment via a workplace setting, and allowing for the
assessment of clinical and occupational outcomes. Finally,
the Headgear Trial will provide much needed information
on the general effectiveness of evidence-based interventions
(BAT and mindfulness) delivered through smartphone
technology.
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